Aurinia Pharmaceuticals
AUPH
Market cap $1.19B

8.80 USD

-0.13

1.46%

At close Jul 11, 4:00 PM EDT

After hours

8.82

+0.02

0.23%

1 day

-1.46%

5 days

17.02%

1 month

8.78%

3 months

18.76%

6 months

13.26%

Year to date

0.34%

1 year

50.17%

5 years

-40.18%

10 years

146.50%

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

100% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]

86% more call options, than puts

Call options by funds: $14.4M | Put options by funds: $7.71M

80% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 20

14% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 58

6% more funds holding

Funds holding: 197 [Q4 2024] → 209 (+12) [Q1 2025]

4.7% more ownership

Funds ownership: 40.37% [Q4 2024] → 45.07% (+4.7%) [Q1 2025]

4% less capital invested

Capital invested by funds: $519M [Q4 2024] → $498M (-$21.3M) [Q1 2025]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for AUPH.

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about AUPH published over the past 30 days

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity

I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year to $60 million and management reaffirm FY2025 guidance. The company has a strong balance sheet, a free cash flow turnaround, and projected profit growth to $0.59/share in FY2025 to support a positive investment outlook.

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025.

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

Zacks Investment Research

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Proactive Investors

Aurinia shares rise ahead of key autoimmune therapy data

Shares of Aurinia Pharmaceuticals (TSX:AUP)(NASDAQ:AUPH) jumped 6.8% to $8.57 on Thursday afternoon as investors looked ahead to the company's first clinical data update for its experimental autoimmune drug AUR200, which Jefferies said could carry significant strategic value. Jefferies upgraded its outlook on the BAFF/APRIL dual inhibitor, noting the upcoming results from a single ascending dose (SAD) study in healthy volunteers could provide important insight into safety, pharmacokinetics and the company's development roadmap.

Aurinia shares rise ahead of key autoimmune therapy data

Zacks Investment Research

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

Investors need to pay close attention to Aurinia Pharmaceuticals (AUPH) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis.

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

Aurinia Pharmaceuticals Inc. AUPH reported first-quarter earnings of 16 cents per share, compared to a loss of 7 cents a year ago. This beat the consensus of 10 cents.

Aurinia Pharma Swings Into Profit As Q1 Sales Jumps 24%, Sticks To Guidance

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2025 Earnings Conference Call May 12, 2025 8:30 AM ET Company Participants Andrea Christopher - Corporate Communications and IR Peter Greenleaf - President and CEO Joe Miller - CFO Greg Keenan - CMO Conference Call Participants Stacy Ku - TD Cowen Maury Raycroft - Jefferies Joseph Schwartz - Leerink Partners Olivia Brayer - Cantor Fitzgerald Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Operator Greetings, and welcome to the Aurinia Pharmaceuticals Inc. Q1 2025 Earnings Call. At this time, all participants are in a listen-only mode.

Aurinia Pharmaceuticals Inc. (AUPH) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.03 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Surpasses Q1 Earnings and Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™